The lack of efficacy of HDAC inhibitors in pancreatic cancer could be linked to the pleiotropic activities of HDACs in cell biology [25], [26] leading to undesired pro-cancer effects. This evidence concerns the gene HDAC9 and pancreatic neoplasm.